Roger B. Cohen
University of Pennsylvania
193 Papers
1.2K Citations
Roger B. Cohen is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 37, co-authored 193 publications. Previous affiliations of Roger B. Cohen include Fox Chase Cancer Center.
Chat about Author
Papers
6508 ORAL CP-751, 871, an anti-IGF-IR antibody, in combination with paclitaxel and carboplatin or paclitaxel and carboplatin alone as first-line treatment for advanced non-small cell lung cancer (NSCLC): A phase Ib/randomized phase II, non-comparative, open label trial
Luis Paz-Ares,Michael Pollak,Peter D. Eisenberg,L. J. Blakely,Paul Haluska,Roger B. Cohen,Harvey Kreisman,C. Melvin,Antonio Gualberto,Daniel D. Karp +9 more
1
P3.02c-069 Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) Predicts Outcomes with Nivolumab in Non-Small Cell Lung Cancer (NSCLC): Topic: IT Biomarkers
Stephen J Bagley,Shawn Kothari,Charu Aggarwal,Joshua Bauml,Evan W. Alley,Tracey L. Evans,John A. Kosteva,Christine Ciunci,Jeffrey C. Thompson,Susan Stonehouse-Lee,Victoria Sherry,Elizabeth Gilbert,Beth Eaby-Sandy,Faith Mutale,Gloria Dilullo,Roger B. Cohen,Anil Vachani,Corey J. Langer +17 more
1
Phase I study of gene mediated cytotoxic immunotherapy (GMCI) for patients with malignant pleural effusion (MPE).
Charu Aggarwal,Andrew R. Haas,Susan Metzger,Laura K. Aguilar,Estuardo Aguilar-Cordova,Andrea G. Manzanera,Evan W. Alley,Tracey L. Evans,Roger B. Cohen,Joshua Bauml,Corey J. Langer,Steven M. Albelda,Daniel H. Sterman +12 more
TL;DR: A tumor-specific immune-stimulator through local delivery of aglatimagene besadenovec, an adenovirus-based vector expressing the HSV-1 thymidine kinase gene (AdV-tk) followe...
1
A phase 2, multicenter, open-label study to evaluate the efficacy and safety of CDX-3379 in combination with cetuximab in patients with advanced head and neck squamous cell carcinoma (HNSCC).
TL;DR: CDX-3379 is a monoclonal antibody with a half-life-extending Fc region YTE mutation that binds a unique epitope, locks ErbB3 in an inactive form, and blocks all Erb B3-dependent downstream signaling that enhances antitumor activity of targeted therapies in preclinical models.
1
HIF inhibition in mRCC: Planned interim analysis of CRLX101 with bevacizumab (bev), a phase 1b/2a.
Stephen M. Keefe,Meliessa Hennessey,Janelle Robinson,Kristine Mykulowicz,Orvar Gunnarsson,Ronac Mamtani,David J. Vaughn,Jean H. Hoffman-Censits,Katherine L. Nathanson,Daniel A. Pryma,Scott Eliasof,Edward Graeme Garmey,Roger B. Cohen,Naomi B. Haas +13 more
TL;DR: CRLX101 (Cerulean Pharma, Inc., Cambridge, MA, USA), a nano pharmaceutical formulation of camptothecin, has been shown in pre-clinical models to inhibit HIF and was combined with bev in the treatment of pts with refractory mRCC to determine the safety and the recommended phase 2 dose (RP2D) of the combination, and the therapeutic activity of treatment.
1